{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:21:38Z","timestamp":1768011698482,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12325-015-0185-5","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T05:33:38Z","timestamp":1424410418000},"page":"108-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Addition of Ivabradine to \u03b2-Blocker Improves Exercise Capacity in Systolic Heart Failure Patients in a Prospective, Open-Label Study"],"prefix":"10.1007","volume":"32","author":[{"given":"A. E.","family":"Bagriy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. V.","family":"Schukina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. V.","family":"Samoilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. A.","family":"Pricolota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. I.","family":"Malovichko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Pricolota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Bagriy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,21]]},"reference":[{"issue":"10","key":"185_CR1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/eurjhf\/hfq154","volume":"12","author":"AP Maggioni","year":"2010","unstructured":"Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12(10):1076\u201384.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"185_CR2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.108.812172","volume":"119","author":"PS Jhund","year":"2009","unstructured":"Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119(4):515\u201323.","journal-title":"Circulation"},{"issue":"5","key":"185_CR3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","volume":"24","author":"M Komajda","year":"2003","unstructured":"Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme\u2014a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464\u201374.","journal-title":"Eur Heart J"},{"issue":"4","key":"185_CR4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/eurheartj\/ehn539","volume":"30","author":"M Komajda","year":"2009","unstructured":"Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 2009;30(4):478\u201386.","journal-title":"Eur Heart J"},{"issue":"6","key":"185_CR5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurjhf\/hfr020","volume":"13","author":"HD Dungen","year":"2011","unstructured":"Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13(6):670\u201380.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"185_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00392-012-0489-2","volume":"102","author":"J Franke","year":"2013","unstructured":"Franke J, Wolter JS, Meme L, et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol. 2013;102(1):23\u201331.","journal-title":"Clin Res Cardiol"},{"key":"185_CR7","doi-asserted-by":"crossref","unstructured":"Russell SJ, Oliver M, Edmunds L, et al. Optimized beta-blocker therapy in heart failure: is there space for additional heart rate control? Br J Cardiol. 2012;19:21\u20133.","DOI":"10.5837\/bjc.2012.001"},{"issue":"9744","key":"185_CR8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"M Bohm","year":"2010","unstructured":"Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886\u201394.","journal-title":"Lancet"},{"issue":"5","key":"185_CR9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","volume":"53","author":"D DiFrancesco","year":"2006","unstructured":"DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399\u2013406.","journal-title":"Pharmacol Res"},{"issue":"9744","key":"185_CR10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet. 2010;376(9744):875\u201385.","journal-title":"Lancet"},{"issue":"2","key":"185_CR11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200831020-00001","volume":"31","author":"I Savelieva","year":"2008","unstructured":"Savelieva I, Camm AJ. I(f) inhibition with ivabradine : electrophysiological effects and safety. Drug Saf. 2008;31(2):95\u2013107.","journal-title":"Drug Saf"},{"issue":"2","key":"185_CR12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2125.2005.02544.x","volume":"61","author":"R Joannides","year":"2006","unstructured":"Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61(2):127\u201337.","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"185_CR13","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","volume":"109","author":"P Mulder","year":"2004","unstructured":"Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109(13):1674\u20139.","journal-title":"Circulation"},{"key":"185_CR14","doi-asserted-by":"crossref","unstructured":"De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10:550\u20135.","DOI":"10.1016\/j.ejheart.2008.04.005"},{"issue":"2","key":"185_CR15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","volume":"151","author":"M Volterrani","year":"2011","unstructured":"Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218\u201324.","journal-title":"Int J Cardiol"},{"issue":"21","key":"185_CR16","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2013.07.027","volume":"62","author":"JC Reil","year":"2013","unstructured":"Reil JC, Tardif JC, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62(21):1977\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"185_CR17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ahj.2012.11.004","volume":"165","author":"AP Ambrosy","year":"2013","unstructured":"Ambrosy AP, Vaduganathan M, Mentz RJ, et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013;165(2):216\u201325.","journal-title":"Am Heart J"},{"issue":"8","key":"185_CR18","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjcard.2010.12.020","volume":"107","author":"M Banach","year":"2011","unstructured":"Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107(8):1208\u201314.","journal-title":"Am J Cardiol"},{"issue":"24","key":"185_CR19","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2008.09.011","volume":"52","author":"PA Meredith","year":"2008","unstructured":"Meredith PA, Ostergren J, Anand I, et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol. 2008;52(24):2000\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"185_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/hrt.2007.134973","volume":"95","author":"CE Raphael","year":"2009","unstructured":"Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009;95(1):56\u201362.","journal-title":"Heart"},{"issue":"2","key":"185_CR21","doi-asserted-by":"crossref","first-page":"H676","DOI":"10.1152\/ajpheart.00564.2002","volume":"284","author":"P Colin","year":"2003","unstructured":"Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284(2):H676\u201382.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"185_CR22","doi-asserted-by":"crossref","first-page":"H672","DOI":"10.1152\/ajpheart.00547.2001","volume":"282","author":"P Colin","year":"2002","unstructured":"Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002;282(2):H672\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"185_CR23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2048872613489305","volume":"2","author":"P Steg","year":"2013","unstructured":"Steg P, Lopez-de-Sa E, Schiele F, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care. 2013;2(3):270\u20139.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"6","key":"185_CR24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10557-011-6327-3","volume":"25","author":"E Amosova","year":"2011","unstructured":"Amosova E, Andrejev E, Zaderey I, et al. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25(6):531\u20137.","journal-title":"Cardiovasc Drugs Ther"},{"key":"185_CR25","doi-asserted-by":"crossref","unstructured":"Zugck C, Martinka P, Stoeckl G, et al. Heart rate control in chronic systolic heart failure patients in Germany: results of a nationwide survey. Eur Heart J. 2013;34(suppl 1)P646.","DOI":"10.1093\/eurheartj\/eht307.P646"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-015-0185-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0185-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T23:30:56Z","timestamp":1566343856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0185-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0185-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}